Aryal Shambhu, Nathan Steven D
Inova Lung Transplant Program, Inova Fairfax Hospital, Falls Church, Virginia, USA.
Curr Opin Organ Transplant. 2018 Jun;23(3):316-323. doi: 10.1097/MOT.0000000000000527.
Lung transplantation is a life-saving treatment for several end stage lung diseases. Over the last two decades, the number of lung transplantation performed worldwide has steadily increased but several thousand people still die every year waiting for lung transplantation. However, the optimal procedure for lung transplantation in non-septic lung conditions remains debatable.
In pulmonary fibrosis and COPD, many recent studies suggest superiority of bilateral lung transplantation over single lung transplantation when long-term survival is evaluated; consequently, bilateral lung transplantation has been favored by many lung transplantation centers. However, the quality of evidence to support the superiority of bilateral lung transplantation remains low in the absence of prospective studies, and other available studies do not show differences in outcomes between the two types of procedure.
In the absence of good high quality evidence, it is difficult to make strong general recommendations for the type of lung transplant, and the decision often has to be individualized. However, the number of recipients on the wait list continues to surpass the amount of available organs and due consideration needs to be given to single lung transplantation as an option whenever possible.
肺移植是治疗多种终末期肺部疾病的挽救生命的疗法。在过去二十年中,全球范围内进行的肺移植数量稳步增加,但每年仍有数千人在等待肺移植过程中死亡。然而,在非感染性肺部疾病中肺移植的最佳术式仍存在争议。
在肺纤维化和慢性阻塞性肺疾病(COPD)方面,近期许多研究表明,在评估长期生存率时,双肺移植优于单肺移植;因此,双肺移植受到了许多肺移植中心的青睐。然而,由于缺乏前瞻性研究,支持双肺移植优越性的证据质量仍然较低,其他现有研究并未显示两种术式在结局上存在差异。
在缺乏高质量有力证据的情况下,很难就肺移植类型给出强有力的一般性建议,决策往往必须个体化。然而,等待名单上的受者数量持续超过可用器官数量,因此在任何可能的情况下都需要适当考虑将单肺移植作为一种选择。